CompletedNCT05113771
Biomarker-guided liafensine study for treatment-resistant depression
About this title
Read the official source — NCT05113771This study evaluated the safety and effectiveness of Liafensine for people with depression.
Medication studyAges 18–70United States + Canada
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Liafensine for people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
- Listed locations
- Huntsville and 44 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: June 29, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 197
- Sponsor
- Denovo Biopharma LLC
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Canada
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT05113771
- Official title
Show the full official title
A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedHuntsville, United States · Phoenix, United States · Garden Grove, United States
39 more locations
- Glendale, United States
- Lafayette, United States
- Oceanside, United States
- Redlands, United States
- Sherman Oaks, United States
- Torrance, United States
- Upland, United States
- Brandon, United States
- Brooksville, United States
- Hollywood, United States
- Miami, United States
- Naples, United States
- Orlando, United States
- Atlanta, United States
- Marietta, United States
- Elgin, United States
- Wichita, United States
- Baltimore, United States
- Gaithersburg, United States
- Boston, United States
- Bloomfield, United States
- Lincoln, United States
- Las Vegas, United States
- Marlton, United States
- Princeton, United States
- Toms River, United States
- Albuquerque, United States
- Glen Oaks, United States
- Columbus, United States
- Allentown, United States
- Moosic, United States
- Dallas, United States
- DeSoto, United States
- Fort Worth, United States
- Houston, United States
- Everett, United States
- Kelowna, Canada
- Markham, Canada
- Toronto, Canada
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Liafensine for people with depression.
Who is behind this study?
The study sponsor is Denovo Biopharma LLC.
Did this study involve medication?
Yes. The study involved medication, including Liafensine and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
